← All trials
NCT06494501
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2024
- Primary completion
- Jun 30, 2032
- Completion date
- Jun 30, 2032
- First posted
- Jul 10, 2024
- Last posted
- Jul 10, 2024
- Enrollment
- 1600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- Icahn School of Medicine at Mount SinaiOfficial
- Icahn School of Medicine at Mount SinaiSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.